Table 4.
Cox UVA and MVA for cohort CRT
| Variable | Cox UVA | Cox MVA | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Facility | ||||||
| Nonacademic | 1 | Ref | 1 | Ref | ||
| Academic | 0.89 | 0.79–0.997 | 0.045 | 0.91 | 0.81–1.03 | 0.14 |
| Age | ||||||
| < 65 | 1 | Ref | 1 | Ref | ||
| ≥ 65 | 1.18 | 1.06–1.32 | 0.0038 | 1.18 | 1.05–1.32 | 0.0055 |
| Gender | ||||||
| Female | 1 | Ref | ||||
| Male | 1.05 | 0.94–1.17 | 0.44 | |||
| Race | ||||||
| White | 1 | Ref | ||||
| Black | 0.99 | 0.85–1.16 | 0.91 | |||
| Other | 0.99 | 0.67–1.48 | 0.98 | |||
| Insurance | ||||||
| None | 1 | Ref | ||||
| Nonprivate | 1.33 | 0.94–1.88 | 0.11 | |||
| Private | 1.09 | 0.77–1.55 | 0.63 | |||
| Income | ||||||
| Above median | 1 | Ref | 1 | Ref | ||
| Below median | 1.21 | 1.08–1.36 | < 0.001 | 1.21 | 1.08–1.36 | < 0.001 |
| Residential setting | ||||||
| Metro | 1 | Ref | ||||
| Urban | 1.02 | 0.88–1.17 | 0.83 | |||
| Rural | 1.14 | 0.83–1.56 | 0.43 | |||
| Charlson-Deyo Score | ||||||
| 0–1 | 1 | Ref | ||||
| ≥ 2 | 1.01 | 0.78–1.30 | 0.94 | |||
| Year of diagnosis | ||||||
| 2004–2007 | 1 | Ref | ||||
| 2008–2011 | 0.92 | 0.81–1.04 | 0.19 | |||
| 2012–2015 | 0.91 | 0.77–1.07 | 0.25 | |||
| Primary tumor site | ||||||
| Head | 1 | Ref | ||||
| Body | 0.96 | 0.85–1.09 | 0.57 | |||
| Tail | 1.04 | 0.76–1.43 | 0.80 | |||
| Tumor size (cm) | ||||||
| < 3.8 | 1 | Ref | ||||
| ≥ 3.8 | 1.08 | 0.96–1.21 | 0.22 | |||
| Clinical N stage | ||||||
| 0 | 1 | Ref | ||||
| 1 | 1.09 | 0.97–1.22 | 0.17 | |||
| Chemotherapy | ||||||
| Single agent | 1 | Ref | 1 | Ref | ||
| Multi agent | 0.79 | 0.70–0.90 | < 0.001 | 0.81 | 0.71–0.92 | 0.0016 |
| Dose escalation | ||||||
| < 55 Gy | 1 | Ref | ||||
| ≥ 55 Gy | 0.91 | 0.78–1.05 | 0.19 | |||
UVA univariate analysis, MVA multivariable analysis, HR hazard ratio, CI confidence interval, Ref reference